A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

TUESDAY, Jan. 21, 2025 (HealthDay News) -- Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions such as substance abuse, psychosis, ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of ...

Two other key studies have shown that patients treated with a GLP-1 drug for diabetes had a lower risk of dementia. All of these studies strongly point to a potential therapeutic use of GLP-1 ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

“Now we have these drugs that work, that are safe, and that are continuing to be investigated in additional conditions as well.” The GLP-1 drugs, originally developed to treat type 2 diabetes, have ...